Core Insights - Arvinas, Inc. announced new preclinical combination data for ARV-393, which will be presented at the AACR Annual meeting, highlighting its potential to be combined with standard lymphoma treatments [1][2] Group 1: Product Information - ARV-393 is an investigational PROteolysis TArgeting Chimera (PROTAC) designed to degrade B-cell lymphoma 6 protein (BCL6), a key driver of B-cell lymphomas [2][4] - The degradation of BCL6 through PROTAC technology aims to address the traditionally undruggable nature of this protein, which plays a significant role in B cell tolerance and proliferation [4] Group 2: Presentation Details - The presentation of ARV-393 will take place on April 28, 2025, at the AACR Annual meeting, with the poster titled "ARV-393, a PROteolysis TArgeting Chimera (PROTAC) BCL6 Degrader, Combined With Biologics or Small-Molecule Inhibitors Induces Tumor Regressions in Diffuse Large B-Cell Lymphoma Models" [3] - The session will focus on experimental and molecular therapeutics, specifically under the title "Degraders and Glues 2" [3] Group 3: Company Overview - Arvinas is a clinical-stage biotechnology company focused on developing therapies that utilize the body's natural protein disposal system to selectively degrade disease-causing proteins [5] - The company is advancing multiple investigational drugs, including vepdegestrant for ER+/HER2- breast cancer, ARV-393 for non-Hodgkin lymphoma, and ARV-102 for neurodegenerative disorders [5]

Core Viewpoint - Arvinas, Inc. (ARVN) is experiencing significant selling pressure, with a 25.4% decline over the past four weeks, but is now positioned for a potential trend reversal due to being in oversold territory and positive earnings expectations from Wall Street analysts [1]. Group 1: Technical Indicators - The Relative Strength Index (RSI) is used to determine if a stock is oversold, with a reading below 30 typically indicating this condition [2]. - ARVN's current RSI reading is 20.28, suggesting that the heavy selling pressure may be exhausting itself and a trend reversal could occur soon [5]. Group 2: Fundamental Indicators - There is a strong consensus among sell-side analysts that ARVN will report better earnings than previously predicted, leading to a 0.7% increase in the consensus EPS estimate over the last 30 days [7]. - ARVN holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises, indicating a potential turnaround [8].

Core Insights - Arvinas, Inc. has presented first-in-human data for its experimental Parkinson's disease treatment, ARV-102, at the 2025 International Conference on Alzheimer's and Parkinson's Diseases [1] Group 1: Clinical Trial Details - The Phase 1 trial included single ascending dose (SAD) cohorts ranging from 10 mg to 200 mg and multiple ascending dose (MAD) cohorts from 10 mg to 80 mg in healthy volunteers [2] - ARV-102, a PROteolysis TArgeting Chimera (PROTAC) LRRK2 degrader, showed a substantial reduction of LRRK2 in cerebrospinal fluid (CSF) [2] - A single oral dose of at least 60 mg ARV-102 resulted in over 50% reduction of LRRK2 protein in CSF and more than 90% reduction in peripheral blood mononuclear cells [3] Group 2: Safety and Tolerability - The trial demonstrated an encouraging safety and tolerability profile, with the most common treatment-related issues being headaches (17.1%) and fatigue (8.6%), although fatigue was more prevalent among placebo recipients (25%) [4] - Early data suggest that ARV-102 was well tolerated among the 47 volunteers across all SAD dose levels [4] Group 3: Future Plans and Market Reaction - In Q4 2024, Arvinas initiated dosing in the SAD cohort of the Phase 1 clinical trial with ARV-102 in patients with Parkinson's disease [5] - The company anticipates completing enrollment and presenting initial data from the ongoing SAD cohort in patients with Parkinson's disease, as well as initiating the MAD cohort in 2025 [5] - Following the announcement, ARVN stock experienced a decline of 4.93%, trading at $6.56 [5]

Core Insights - Arvinas, Inc. presented data from the first-in-human clinical trial of ARV-102, demonstrating its potential in reducing LRRK2 protein associated with neurodegenerative diseases like Parkinson's disease and progressive supranuclear palsy [1][3][7] Group 1: Clinical Trial Findings - ARV-102 was well tolerated and showed substantial LRRK2 reduction in both central and peripheral systems, indicating effective protein degradation [1][5] - The Phase 1 trial included a single ascending dose (SAD) cohort with doses from 10 mg to 200 mg and a multiple ascending dose (MAD) cohort with doses from 10 mg to 80 mg [2][3] - At doses of 60 mg or higher, ARV-102 achieved over 50% LRRK2 reduction in cerebrospinal fluid (CSF) and over 90% reduction in peripheral blood mononuclear cells (PBMCs) [5][9] Group 2: Safety and Tolerability - No serious adverse events were reported, and the drug was generally safe and well tolerated among healthy volunteers [4][5] - Common treatment-related adverse events included headache (17.1%) and fatigue (8.6%), with procedural pain from lumbar puncture reported in 28.6% of treated individuals [9] Group 3: Pharmacokinetics and Pharmacodynamics - ARV-102 demonstrated dose-dependent increases in exposure in both plasma and CSF, with a median terminal plasma half-life of 73 hours [9] - The drug's pharmacodynamic effects included significant reductions in phospho-Rab10T73 and bis(monoacylglycerol)phosphate (BMP) in urine, indicating engagement with downstream LRRK2 pathways [5][9] Group 4: Future Directions - Arvinas plans to continue the clinical program for ARV-102, with ongoing trials in patients with Parkinson's disease and expectations to present initial data in 2025 [7][10]

Core Insights - Arvinas, Inc. is set to present data from its first-in-human study of ARV-102, a drug targeting LRRK2, at the International Conference on Alzheimer's and Parkinson's Diseases in April 2025 [1][3] - ARV-102 is designed as a PROTAC to degrade LRRK2, which is linked to Parkinson's disease and progressive supranuclear palsy [2][4] - The presentation will focus on the safety, pharmacokinetics, and pharmacodynamics of ARV-102 in healthy males [3] Company Overview - Arvinas is a clinical-stage biotechnology company focused on developing therapies for serious diseases using its PROTAC platform [5] - The company is advancing multiple investigational drugs, including vepdegestrant for breast cancer, ARV-393 for non-Hodgkin lymphoma, and ARV-102 for neurodegenerative disorders [5] - Arvinas is headquartered in New Haven, Connecticut, and aims to improve patient outcomes through innovative protein degradation therapies [5]

NEW HAVEN, Conn., March 27, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical- stage biotechnology company working to develop a new class of drugs based on targeted protein degradation, today announced that data from the first-in-human study evaluating single-ascending and multiple-ascending doses in healthy volunteers of ARV-102 will be presented at the International Conference on Alzheimer's and Parkinson's Diseases (AD/PD™), April 1-5, 2025 in Vienna, Austria. ARV-102 is Arvinas' investig ...

Core Viewpoint - Arvinas, Inc. (ARVN) has experienced significant selling pressure, resulting in a 54.9% decline in stock price over the past four weeks, but analysts anticipate better earnings than previously predicted, indicating a potential turnaround for the company [1]. Group 1: Stock Performance and Technical Indicators - The stock is currently in oversold territory, with a Relative Strength Index (RSI) reading of 23.18, suggesting that the heavy selling may be exhausting itself and a price reversal could be imminent [5][6]. - A stock is generally considered oversold when its RSI falls below 30, indicating a potential entry opportunity for investors [2][3]. Group 2: Earnings Estimates and Analyst Sentiment - Over the last 30 days, the consensus earnings per share (EPS) estimate for ARVN has increased by 1.2%, reflecting a strong agreement among analysts to raise earnings estimates for the current year [6]. - ARVN holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises, further supporting the potential for a turnaround [7].

Core Viewpoint - Arvinas, Inc. (ARVN) has experienced significant selling pressure, resulting in a 54% decline in stock price over the past four weeks, but analysts anticipate better earnings than previously expected, indicating a potential rebound [1]. Group 1: Technical Indicators - The Relative Strength Index (RSI) for ARVN is currently at 24.51, indicating that the stock is in oversold territory, which may suggest an imminent trend reversal [5]. - RSI is a momentum oscillator that helps identify whether a stock is overbought or oversold, with a reading below 30 typically indicating oversold conditions [2][3]. Group 2: Fundamental Indicators - There has been a consensus among sell-side analysts to raise earnings estimates for ARVN, leading to a 1.2% increase in the consensus EPS estimate over the last 30 days, which often correlates with price appreciation [6]. - ARVN holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises, further supporting the potential for a turnaround [7].

Company Overview - Arvinas, Inc. (ARVN) shares increased by 8.8% to close at $9.03, following a trading session with significantly higher volume than usual, despite a 53.1% loss over the past four weeks [1] - The stock's recovery came after mixed results from a late-stage breast cancer study of vepdegestrant, which is in phase III VERITAC-2 study for advanced or metastatic breast cancer [2] Financial Performance - The company is projected to report a quarterly loss of $0.85 per share, reflecting a year-over-year increase of 12.4%, with expected revenues of $58.14 million, marking a 129.8% increase from the previous year [3] - The consensus EPS estimate for the upcoming quarter has been revised 26.9% higher in the last 30 days, indicating a positive trend that may lead to price appreciation [4] Industry Context - Arvinas is part of the Zacks Medical - Biomedical and Genetics industry, where another company, Certara, Inc. (CERT), saw a 1% increase to $11.01 but has a -21.4% return over the past month [4] - Certara's consensus EPS estimate has decreased by 23.8% to $0.10, showing no change from the previous year, and it currently holds a Zacks Rank of 3 (Hold) [5]

Core Insights - Arvinas, Inc. and Pfizer Inc. announced topline results from the Phase 3 VERITAC-2 trial for vepdegestrant in advanced or metastatic breast cancer patients [1][2] - The trial focused on estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) patients who had disease progression after prior treatments [2] Trial Results - The trial met its primary endpoint in the estrogen receptor 1-mutant (ESR1m) population, showing a statistically significant improvement in progression-free survival (PFS) compared to fulvestrant [3] - The results surpassed the pre-specified target hazard ratio of 0.60 in the ESR1m population [4] - No statistical significance was found in PFS improvement in the intent-to-treat (ITT) population, and overall survival data was not mature at the time of analysis [4] Future Plans and Designations - The trial will continue to evaluate overall survival as a key secondary endpoint [5] - Vepdegestrant was generally well tolerated during the trial [5] - Detailed results will be presented at a medical meeting later this year, and the FDA granted Fast Track designation for vepdegestrant for monotherapy in eligible patients [5] Market Reaction - Following the trial results, ARVN stock experienced a decline of 52.4%, trading at $8.35 [6]